CORTISONE ACETATE (cortisone acetate) by Molecular Devices is clinical pharmacology: naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. First approved in 2001.
Drug data last refreshed 12h ago · AI intelligence enriched 2d ago
Cortisone acetate is an oral glucocorticoid tablet used for replacement therapy in adrenocortical deficiency and as an anti-inflammatory agent across multiple organ systems. It works by modifying immune responses and producing profound metabolic effects characteristic of naturally occurring glucocorticoids. The drug has been approved since 2001 and remains a foundational steroid therapy.
Product approaching loss of exclusivity with moderate competitive pressure (30% intensity), suggesting defensive positioning and potential team consolidation.
CLINICAL PHARMACOLOGY: Naturally occurring glucocorticoids (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. They are also used for their potent anti-inflammatory effects in disorders of many organ…
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Pharmacokinetics and Bioavailability of Hydrocortisone Acetate Suppositories
Working on cortisone acetate offers limited growth opportunity due to approaching LOE and zero linked job openings; career value lies in managing mature product decline and defending against generic competition. This role suits professionals skilled in cost-containment, reimbursement defense, and portfolio optimization in a commoditized segment.
Worked on CORTISONE ACETATE at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo